Relationship between capsule formation and drug resistance of Cryptococcus

The polysaccharide capsule of Cryptococcus plays a pivotal role in both its pathogenicity and resistance to antifungal therapies. This capsule acts as a physical barrier, impeding the penetration of antifungal drugs and thereby reducing their efficacy in killing fungal cells. Moreover, chemical modifications of the capsule, including acetylation and xylosylation, further enhance its resistance to drugs, particularly azole antifungals. Beyond its role in drug resistance, the capsule also facilitates immune evasion, enabling Cryptococcus to survive and persist within the host by interfering with the host's immune defenses. Recent studies have highlighted the importance of glucuronoxylomannan (GXM) and its modified sugar derivatives in the structure and function of the capsule. However, the precise mechanisms governing the transport and interactions involved in the assembly of the capsule’s fibrillar network remain poorly understood. Furthermore, alterations in capsule composition, density, and modification significantly influence the pathogen's resistance to antibiotics. Future research is needed to elucidate the synthesis, modification, and assembly processes of the capsule, as well as its specific contributions to drug resistance and immune evasion. Such insights could provide new therapeutic targets and strategies for combating Cryptococcus infections.